Skip to content

Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker

Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03659643
Enrollment
300
Registered
2018-09-06
Start date
2018-01-01
Completion date
2020-10-01
Last updated
2018-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Keywords

MCI, Alzheimer´s disease, Lewy Body Dementia, EEG

Brief summary

Multi center study of six Memory Clinics in four Nordic countries in validating a prognostic diagnostic investigation of qEEG in Mild Cognitive Impairment (MCI). The study is in two parts, the first one is a follow up of a previous study conducted in 2011-2013 and the second half is new recruitment with two years follow up. End points are diagnosis of a dementing disorder, primarily dementia of Alzheimer´s type.

Detailed description

The Nordic Network in Dementia Diagnostics (NIDD) conducted a study in 2011-2013 on qEEG using a method of Statistical Pattern Recognition (SPR) in six academic Memory Clinics in four Nordic countries. In the current study, those from the former study diagnosed either with Mild Cognitive Impairment (MCI; n= 120) or with Subjective Cognitive Impairment (SCI; n=60) are contacted again and evaluated for cognitive impairment. The EEG registered at entry in the former study is considered in relation to their current diagnosis (SCI,MCI or dementia) and thereby, the prognostic value of the method is evaluated. In the second part of the study (n=120), new patients evaluated in the Memory Clinics and diagnosed with MCI (not SCI) are invited to participate for a two year follow up. In the diagnostic work-up, simple screening tests and information from a close relative form the basis of the cognitive status (SCI;MCI, Dementia). In evaluating the cause of cognitive impairment, detailed neuropsychological testing is performed as well as MRI of the brain and CSF for Alzheimer´s markers. qEEG with SPR analysis is registered but the clinician is blinded to its outcome. The end point in both parts of the study is a diagnosis of a dementing disorder.

Interventions

DIAGNOSTIC_TESTEEG with SPR analysis

qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.

Sponsors

Ullevaal University Hospital
CollaboratorOTHER
Karolinska University Hospital
CollaboratorOTHER
Rigshospitalet, Denmark
CollaboratorOTHER
Zealand University Hospital
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
Kavli Research Foundation, Bergen Norway
CollaboratorUNKNOWN
Jon Snaedal
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Group 1: Individuals diagnosed with either SCI or MCI during 2011-2013 Group 2: Individuals diagnosed with MCI at entry of the study \-

Exclusion criteria

* Age \<50 years or \>85 years * Medically or psychologically unstable * Living outside the capital region

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis of dementiaGroup 1: 4-6 years after initial registration, Group 2: 1-2 years after initial registrationThe type of dementia is registered

Secondary

MeasureTime frameDescription
CERAD ten word testGroup 1: 4-6 years after initial registration, Group 2: 1-2 years after initial registrationImmediate recall (0-30 words); delayed recall (0-10words) and recognition (0-20 words)

Countries

Iceland

Contacts

Primary ContactJon Snaedal, MD
jsnaedal@landspitali.is+354 864 0478
Backup ContactHalla Arnardottir, RN
hallarn@landspitali.is354 543 5711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026